RSV Vaccine‌ Guidance for at-risk Populations

‌ France’s public health agency, Santé ‌Publique France (SPF),​ is ⁤recommending Respiratory Syncytial Virus (RSV) vaccination for⁢ individuals aged 75 ‌and over, ⁣and ‍for those aged 65 and⁤ over⁢ with chronic respiratory ​illnesses – particularly Chronic Obstructive Pulmonary Disease (COPD) – or cardiac ⁤conditions like​ heart failure. these conditions can ⁢be⁤ significantly worsened by an RSV infection.
​

⁤ Currently available RSV vaccines include mResvia (Moderna), Arexvy (GSK), and ‌Abrysvo (Pfizer). As of November 5, ​2025, none of these vaccines are reimbursed ‌by teh French ‍healthcare system. ​ The Abrysvo ⁢vaccine is currently ​not reimbursed for individuals under 60. SPF’s‍ bulletin on‍ acute respiratory infections ⁣notes that the‌ need for annual booster doses has⁣ not yet been established.

Other Respiratory Infections: ⁢Flu and COVID-19

‍ ‍⁣ Influenza activity is‌ currently at baseline levels across all regions of France, except for ⁤mayotte, which is entering ‍its pre-epidemic phase as of the week of October 20, 2025. COVID-19 cases are decreasing in urban areas and remaining generally stable in⁣ hospitals.